

Attorney Docket No. 9151-6

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Wheeler et al.
Serial No.: 09/823,069
Filed: March 30, 2001
For: METHODS AND COMPOSITIONS UTILIZING AN
ALTERNATIVE SPLICE VARIANT OF THE SIGMA-1 RECEPTOR

Date: July 18, 2001

Assistant Commissioner for Patents
Washington, DC 20231

**AMENDMENT AND STATEMENT IN SUPPORT OF FILING A
SEQUENCE LISTING UNDER 37 CFR § 1.821(f)**

Sir:

Please reconsider the above-captioned application in view of the following amendments and remarks.

AMENDMENT

Please insert supplemental pages 1 through 5, enclosed herewith, after the claims of the present application. The supplemental pages comprise the Sequence Listing for the application.

REMARKS AND STATEMENT

A Notice to File Missing Parts Of Non-Provisional Application has been issued in the present case, and Applicants have been instructed to comply with the requirements for patent applications containing nucleotide sequences and/or amino acid sequences. In response to the Notice, Applicants hereby submit a paper copy of a Sequence Listing in the form of supplemental pages numbered 1 through 5, which should be inserted into the present application after the claims.

The supplemental pages submitted herewith contain the Sequence Listing required by 37 C.F.R. § 1.821(c) for nucleotide and peptide sequences described in the specification, and are submitted as substitute (supplemental) sheets as required by 37 C.F.R. § 1.825(a). The sequences are also provided on computer diskette in a computer readable form as required by 37 C.F.R. §§ 1.821(e) and 1.824.

09/823,069 "07/2001"

In re: Wheeler et al.
Serial No.: 09/823,069
Filed: March 30, 2001
Page 2

I hereby state as required by 37 C.F.R. § 1.821(f) that the content of the paper copy of the Sequence Listing and the computer readable copy are the same.

I also hereby state as required by 37 C.F.R. §1.825(a) that the substitute sheets contain no new matter.


Respectfully submitted,


Sorojini J. Biswas
Registration No. 39,111

CUSTOMER NUMBER 20792
Myers Bigel Sibley & Sajovec
PO Box 37428
Raleigh NC 27627
Tel (919) 854-1400
Fax (919) 854-1401

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, DC 20231, on July 18, 2001.


Meredith Schuessler
Date of Signature: July 18, 2001

09/823,069
07/2001



SEQUENCE LISTING

<110> ~~Patent & Trademark Office~~, Kenneth
Mach, Robert
Childers, Steven
Shelness, Gregory
Wang, Li-Ming

<120> METHODS AND COMPOSITIONS UTILIZING AN ALTERNATIVE SPLICE VARIANT OF THE SIGMA-1 RECEPTOR

<130> 9151.6

<140> 09/823,069

<141> 2001-03-30

<150> US 60/193,694

<151> 2000-03-31

<160> 6

<170> PatentIn version 3.0

<210> 1

<211> 579

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(579)

<400> 1

atg	cag	tgg	gcc	gtg	ggc	cgg	cgg	tgg	gcg	tgg	gcc	gcg	ctg	ctc	ctg	48
Met	Gln	Trp	Ala	Val	Gly	Arg	Arg	Trp	Ala	Trp	Ala	Ala	Leu	Leu	Leu	
1				5				10					15			

gct	gtc	gca	gcg	gtg	ctg	acc	cag	gtc	gtc	tgg	ctc	tgg	ctg	ggg	acg	96
Ala	Val	Ala	Ala	Val	Leu	Thr	Gln	Val	Val	Trp	Leu	Trp	Leu	Gly	Thr	
		20					25				30					

cag	agc	ttc	gtc	ttc	cag	cgc	gaa	gag	ata	gcg	cag	ttg	gcg	cgg	cag	144
Gln	Ser	Phe	Val	Phe	Gln	Arg	Glu	Glu	Ile	Ala	Gln	Leu	Ala	Arg	Gln	
		35				40					45					

tac	gct	ggg	ctg	gac	cac	gag	ctg	gcc	ttc	tct	cgt	ctg	atc	gtg	gag	192
Tyr	Ala	Gly	Leu	Asp	His	Glu	Leu	Ala	Phe	Ser	Arg	Leu	Ile	Val	Glu	
	50				55				60							

ctg	cgg	cgg	ctg	cac	cca	ggc	cac	gtg	ctg	ccc	gac	gag	gag	ctg	cag	240
Leu	Arg	Arg	Leu	His	Pro	Gly	His	Val	Leu	Pro	Asp	Glu	Glu	Leu	Gln	
65				70				75						80		

tgg	gtg	ttc	gtg	aat	gcg	ggg	ggc	tgg	atg	ggc	gcc	atg	tgc	ctt	ctg	288
Trp	Val	Phe	Val	Asn	Ala	Gly	Gly	Trp	Met	Gly	Ala	Met	Cys	Leu	Leu	
				85				90						95		

cac gcc tcg ctg tcc gag tat gtg ctg ctc ttc ggc acc gcc ttg ggc 336
His Ala Ser Leu Ser Glu Tyr Val Leu Leu Phe Gly Thr Ala Leu Gly
100 105 110

tcc cgc ggc cac tcg ggg gag acg gta gta cac ggg cct ggt gag gca 384
Ser Arg Gly His Ser Gly Glu Thr Val Val His Gly Pro Gly Glu Ala
115 120 125

aca gct gtg gag tgg ggg cca aac aca tgg atg gtg gag tac ggc cgg 432
Thr Ala Val Glu Trp Gly Pro Asn Thr Trp Met Val Glu Tyr Gly Arg
130 135 140

ggc gtc atc cca tcc acc ctg gcc ttc gcg ctg gcc gac act gtc ttc 480
Gly Val Ile Pro Ser Thr Leu Ala Phe Ala Leu Ala Asp Thr Val Phe
145 150 155 160

agc acc cag gac ttc ctc acc ctc ttc tat act ctt cgc tcc tat gct 528
Ser Thr Gln Asp Phe Leu Thr Leu Phe Tyr Thr Leu Arg Ser Tyr Ala
165 170 175

cgg ggc ctc cgg ctt gag ctc acc acc tac ctc ttt ggc cag gac cct 576
Arg Gly Leu Arg Leu Glu Leu Thr Thr Tyr Leu Phe Gly Gln Asp Pro
180 185 190

tga 579

<210> 2
<211> 192
<212> PRT
<213> Homo sapiens

<400> 2

Met Gln Trp Ala Val Gly Arg Arg Trp Ala Trp Ala Ala Leu Leu Leu
1 5 10 15

Ala Val Ala Ala Val Leu Thr Gln Val Val Trp Leu Trp Leu Gly Thr
20 25 30

Gln Ser Phe Val Phe Gln Arg Glu Glu Ile Ala Gln Leu Ala Arg Gln
35 40 45

Tyr Ala Gly Leu Asp His Glu Leu Ala Phe Ser Arg Leu Ile Val Glu
50 55 60

Leu Arg Arg Leu His Pro Gly His Val Leu Pro Asp Glu Glu Leu Gln
65 70 75 80

Trp Val Phe Val Asn Ala Gly Gly Trp Met Gly Ala Met Cys Leu Leu
85 90 95

His Ala Ser Leu Ser Glu Tyr Val Leu Leu Phe Gly Thr Ala Leu Gly
 100 105 110

Ser Arg Gly His Ser Gly Glu Thr Val Val His Gly Pro Gly Glu Ala
 115 120 125

Thr Ala Val Glu Trp Gly Pro Asn Thr Trp Met Val Glu Tyr Gly Arg
 130 135 140

Gly Val Ile Pro Ser Thr Leu Ala Phe Ala Leu Ala Asp Thr Val Phe
 145 150 155 160

Ser Thr Gln Asp Phe Leu Thr Leu Phe Tyr Thr Leu Arg Ser Tyr Ala
 165 170 175

Arg Gly Leu Arg Leu Glu Leu Thr Thr Tyr Leu Phe Gly Gln Asp Pro
 180 185 190

<210> 3
 <211> 579
 <212> DNA
 <213> Mus musculus

<220>
 <221> CDS
 <222> (1)..(579)

<400> 3
 atg ccg tgg gcc gcg gga cgg cgg tgg gca tgg atc acc ctg att ctg 48
 Met Pro Trp Ala Ala Gly Arg Arg Trp Ala Trp Ile Thr Leu Ile Leu
 1 5 10 15
 act att atc gca gtg ctg atc cag gcc gcc tgg ttg tgg ctg ggc act 96
 Thr Ile Ile Ala Val Leu Ile Gln Ala Ala Trp Leu Trp Leu Gly Thr
 20 25 30
 caa aac ttc gtc ttc tct aga gaa gaa ata gcg cag ctt gct cga cag 144
 Gln Asn Phe Val Phe Ser Arg Glu Glu Ile Ala Gln Leu Ala Arg Gln
 35 40 45
 tat gcg ggg ctg gac cat gag ctt gcc ttc tct cgg ctg atc gtg gag 192
 Tyr Ala Gly Leu Asp His Glu Leu Ala Phe Ser Arg Leu Ile Val Glu
 50 55 60
 ctg cgg agg ctg cac cca ggc cac gtg ctg ccg gat gag gag ctg cag 240
 Leu Arg Arg Leu His Pro Gly His Val Leu Pro Asp Glu Glu Leu Gln
 65 70 75 80
 tgg gta ttt gtg aac gcg ggc ggc tgg atg ggc gcc atg tgt att ctg 288
 Trp Val Phe Val Asn Ala Gly Gly Trp Met Gly Ala Met Cys Ile Leu

	85							90						95						
cac gcc tgc ctg tct gag tac gtg	ctg ctc ttc ggc acc gcc ctg ggc	336																		
His Ala Ser Leu Ser Glu Tyr Val	Leu Leu Phe Gly Thr Ala Leu Gly																			
100	105	110																		
tcc cat ggc cat tcg gga gag aca gtt gta cac ggg cct gga gaa gca	384																			
Ser His Gly His Ser Gly Glu Thr Val Val His Gly Pro Gly Glu Ala																				
115	120	125																		
acg gct ctg gag tgg gga cca aac acg tgg atg gtg gag tac ggc cgg	432																			
Thr Ala Leu Glu Trp Gly Pro Asn Thr Trp Met Val Glu Tyr Gly Arg																				
130	135	140																		
ggt gtt att ccg tct acc ctg ttc ttt gca cta gcc gac acc ttc ttc	480																			
Gly Val Ile Pro Ser Thr Leu Phe Phe Ala Leu Ala Asp Thr Phe Phe																				
145	150	155	160																	
ggc acc cag gac tac ctc aca ctc ttc tat acc ctt cgg gcc tat gcc	528																			
Gly Thr Gln Asp Tyr Leu Thr Leu Phe Tyr Thr Leu Arg Ala Tyr Ala																				
165	170	175																		
cgg ggc ctc cgg ctt gag ctt acc acc tac ctc ttt ggc caa gac tcc	576																			
Arg Gly Leu Arg Leu Glu Leu Thr Thr Tyr Leu Phe Gly Gln Asp Ser																				
180	185	190																		
tga	579																			
<210>	4																			
<211>	192																			
<212>	PRT																			
<213>	Mus musculus																			
<400>	4																			
Met Pro Trp Ala Ala Gly Arg Arg Trp Ala Trp Ile Thr Leu Ile Leu																				
1	5	10	15																	
Thr Ile Ile Ala Val Leu Ile Gln Ala Ala Trp Leu Trp Leu Gly Thr																				
20	25	30																		
Gln Asn Phe Val Phe Ser Arg Glu Glu Ile Ala Gln Leu Ala Arg Gln																				
35	40	45																		
Tyr Ala Gly Leu Asp His Glu Leu Ala Phe Ser Arg Leu Ile Val Glu																				
50	55	60																		
Leu Arg Arg Leu His Pro Gly His Val Leu Pro Asp Glu Glu Leu Gln																				
65	70	75	80																	
Trp Val Phe Val Asn Ala Gly Gly Trp Met Gly Ala Met Cys Ile Leu																				

85

90

95

His Ala Ser Leu Ser Glu Tyr Val Leu Leu Phe Gly Thr Ala Leu Gly
 100 105 110

Ser His Gly His Ser Gly Glu Thr Val Val His Gly Pro Gly Glu Ala
 115 120 125

Thr Ala Leu Glu Trp Gly Pro Asn Thr Trp Met Val Glu Tyr Gly Arg
 130 135 140

Gly Val Ile Pro Ser Thr Leu Phe Phe Ala Leu Ala Asp Thr Phe Phe
 145 150 155 160

Gly Thr Gln Asp Tyr Leu Thr Leu Phe Tyr Thr Leu Arg Ala Tyr Ala
 165 170 175

Arg Gly Leu Arg Leu Glu Leu Thr Thr Tyr Leu Phe Gly Gln Asp Ser
 180 185 190

<210> 5
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <222> (1)..(31)
 <223> Synthetic Oligonucleotide Primer.

<400> 5
 gaacgaattc agaagtcctt gggccgcggg a

31

<210> 6
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <222> (1)..(31)
 <223> Synthetic Oligonucleotide Primer.

<400> 6
 taacggtacc tcaggagtct tggccaaaga g

31